Stockscreener 앱 받기
1.83
3.17%
-0.06
시간 외 거래:
1.90
0.07
+3.83%
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC - Dermatology Times
Small cap wrap: EnWave, Medicus Pharma, Ocean Power Technologies, EDM Resources, C3 Metals… - Proactive financial news
Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study - Proactive financial news
Medicus Pharma Completes Patient Enrollment for Phase 2 BCC Treatment Study - TipRanks
Medicus Pharma completes enrollment of 90 patients for Phase 2 study - TipRanks
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Manila Times
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) - GlobeNewswire
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - Greenville Online
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Norwich Bulletin
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 - Victorville Daily Press
Medicus Pharma’s Warrant Inducement Agreement Announced - TipRanks
Medicus Pharma Elevates President Carolyn Bonner to CFO as Clinical Pipeline Accelerates - MyChesCo
Medicus Pharma Ltd. To Present at Brookline Capital Markets - Daytona Beach News-Journal
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE - Daytona Beach News-Journal
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Asheville Citizen Times
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing - The Times Telegram
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject - Daytona Beach News-Journal
Medicus Pharma secures $5.1 million from warrant exercise agreement By Investing.com - Investing.com Nigeria
Medicus Pharma secures $5.1 million from warrant exercise agreement - Investing.com India
Medicus Pharma Shakes Up Executive Ranks as President Takes on CFO Role - MSN
How Medicus Pharma Ltd. stock reacts to oil prices2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
How Medicus Pharma Ltd. Equity Warrant stock trades during market volatilityJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Is Medicus Pharma Ltd. Equity Warrant stock attractive for retirement portfoliosTrade Risk Report & Free Long-Term Investment Growth Plans - Newser
Medicus Pharma appoints Carolyn Bonner as CFO - Pharmafile
How currency fluctuations impact Medicus Pharma Ltd. stockJuly 2025 Institutional & Momentum Based Trading Ideas - Newser
Medicus Pharma Ltd. Strengthens Leadership and Expands Clinical Trials - MSN
Medicus Pharma promotes president to chief financial officer - Pennsylvania Business Report -
Should I buy Medicus Pharma Ltd. (N460) stock before earnings seasonWeekly Risk Summary & Scalable Portfolio Growth Methods - Newser
Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch - marketscreener.com
How Medicus Pharma Ltd. (N460) stock gains from tech spendingJuly 2025 Setups & Safe Capital Allocation Plans - Newser
How big funds are accumulating Medicus Pharma Ltd. (N460) stockInsider Buying & Technical Confirmation Trade Alerts - Newser
Is Medicus Pharma Ltd. (N460) stock a fit for income portfoliosJuly 2025 Pullbacks & Expert Verified Movement Alerts - Newser
Medicus Pharma shares updates on basal cell carcinoma trials - Pharmafile
1.77%
2.24%
자본화:
|
볼륨(24시간):